共 18 条
[1]
Bataille R., Jourdan M., Zhang X.G., Klein B., Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias, Journal of Clinical Investigation, 84, pp. 2008-2011, (1989)
[2]
Chiesa J.J., (1991)
[3]
Dewald G.W., Kyle R.A., Hicks G.A., Greipp P.R., The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis, Blood, 66, pp. 380-390, (1985)
[4]
Durie B.G.M., Salmon S.E., A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival, Cancer, 36, pp. 842-854, (1975)
[5]
Facon T., Lai J.L., Nataf E., Preudhomme C, Zandecki M., Hammad M., Wattel E., Jouet J.P., Bauters F., Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients, British Journal of Haematology, 84, pp. 743-745, (1993)
[6]
Facon T., Lai J.L., Trillot N., Flactif M., Zandecki M., Bauters F., Cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in patients with multiple myeloma: a report on 100 patients. (Abstract), Blood, 82, (1993)
[7]
Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B., Plasma cell karyotype in multiple myeloma, Blood, 71, pp. 453-456, (1988)
[8]
Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature, (1991)
[9]
Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R., Paracrine rather than autocrine regulation of myeloma‐cell growth and differentiation by interleukin‐6, Blood, 73, pp. 517-526, (1989)
[10]
Liang W., Hopper J.E., Rowley J.D., Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders, Cancer, 44, pp. 630-644, (1979)